Skip to main content

Table 3 Baseline characteristics of ACPA-negative RA patients per MBDA category

From: ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation

 MBDA categoryp value
< 30 (n = 17)30–44 (n = 29)> 44 (n = 95)
Age in years, mean (SD)48 (16)60 (13)62 (14)< 0.001
Female, n (%)13 (76)22 (76)58 (61)0.21
Symptom duration in weeks, median (IQR)26 (8–41)12 (4–25)12 (5–22)0.13
(Sub)acute symptom onset, n (%)3 (20)7 (26)46 (52)0.01
66-SJC, median (IQR)3 (2–7)6 (3–13)9 (3–13)0.08
68-TJC, median (IQR)12 (9–19)11 (5–21)9 (4–17)0.23
RF positivity, n (%)7 (41)9 (31)33 (35)0.78
ESR (mm/h), median (IQR)9 (4–14)14 (6–33)33 (19–48)< 0.001
CRP (µg/mL), median (IQR)3 (3–3)3 (3–4)22 (11–44)< 0.001
  1. Characteristics of ACPA-negative RA patients with low, moderate or high MBDA score were compared with one-way ANOVA, chi-square test and Kruskal-Wallis test, as appropriate
  2. Symptom duration, time between symptom onset and inclusion in cohort; (sub)acute symptom onset, prompt onset of symptoms (< 1 week); SD, standard deviation; IQR, interquartile range; SJC, 66-swollen joint count; TJC, 68-tender joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; RA, rheumatoid arthritis; MBDA, multi-biomarker disease activity